We have previously described a monoclonal antibody (FA6-152), obtained by immunizing mice with fetal human erythrocytes [Edelman, Vinci, Villeval, Vainchenker, Henri, Miglierina, Rouger, Reviron, BretonGorius, Sureau & Edelman (1986) Blood 67, 56-63]. The antibody labelled fetal, but not adult, erythrocytes and bound to both fetal and adult platelets and monocytes. In the present study we have characterized the antigen recognized by FA6-152 on human platelets and on cells of the erythroid lineage at different stages of maturation. FA6-152 precipitated a chymotrypsin-resistant 88 kDa sialoglycoprotein from both iodinated and periodate/NaB3H4-surface-labelled platelets which corresponds to glycoprotein IV, the platelet thrombospondin (TSP) receptor. After neuraminidase treatment, a shift of the apparent molecular mass from 88 kDa to 85 kDa was observed. Scatchard analysis revealed that '25I-FA6-152 bound saturably with high affinity to a single class of platelet binding sites (Kd 6.4 + 0.6 nM). The number of FA6-152 IgG molecules bound per platelet was 25400 + 8800 (n = 4) and did not change upon thrombin activation of platelets. At low doses of oc-thrombin (0.025 unit), FA6-152 inhibited platelet aggregation as well as endogenous TSP binding to the platelet surface. Immunofluorescence labelling of bone-marrow cells and of cultures in vitro of burst-forming units-erythroid (BFU-E) and colony-forming units-erythroid (CFU-E) revealed that the FA6-152 antigen is a very early marker of erythroid differentiation and that its expression declines during maturation. Immunochemical identification of the FA6-152 antigen on fetal erythroblasts and fetal mature erythrocytes revealed a 78 kDa glycoprotein migrating just in front of the glycophorin A dimer. The antigen, which was absent from adult mature erythrocytes, was also detected in human erythroleukaemic (HEL) cells where FA6-152 precipitated two bands of molecular mass 85 and 88 kDa. Our data establish the existence of a previously unidentified 78 kDa erythroblast cell-surface glycoprotein whose expression is developmentally regulated during erythroid differentiation and which is immunologically related to the 88 kDa platelet TSP receptor.
INTRODUCTION
In many developmental systems, membrane glycoproteins have been identified which appear at the cell surface in concert with an initial requirement for cell-cell adhesion. In the bone marrow, normal haematopoietic cell regulation requires the interaction of haematopoietic progenitor cells with marrow stromal cells, which are essential for the lodging, proliferation and eventual differentiation of these progenitors into mature blood cells (Dexter, 1979) . Erythroid cells exhibit selective binding to fibronectin through a 140 kDa fibronectin receptor. During differentiation oferythroblasts to reticulocytes in vivo (Patel & Lodish, 1986) or of murine erythroleukaemic (MEL) cells in vitro (Giancotti et al., 1986) , the fibronectin receptor is lost from the surface of the cells, leading to a loss of adhesiveness to fibronectin.
Coulombel et al. (1988) recently reported incomplete inhibition, by anti-fibronectin antibodies, of humanerythroid-progenitor-cell adhesion to extracellular matrixes secreted by human marrow fibroblasts, suggesting that other matrix molecules might be involved in erythroid-progenitor attachment.
Like fibronectin, TSP is a multifunctional glycoprotein which binds to a large number of macromolecules and mediates cell adhesion in vitro [for a review, see Lawler (1986) ]. Current data have now provided evidence that TSP is synthesized and secreted by a variety of cells, including endothelial cells (Mosher et al., 1982) , fibroblasts (Jaffe et al., 1983) , smooth-muscle cells (Raugi et al., 1982) , glial cells (Asch et al., 1986) , monocytes and macrophages (Jaffe et al., 1985) , and is incorporated into the extracellular matrix of growing cells (Mumby et al., 1984) . In addition, specific binding of 25I-TSP to platelets (Wolff et al., 1986) , endothelial cells (Murphy-Ullrich & Mosher, 1987) , fibroblasts (McKeown-Longo et al., 1984) and human tumour-cell lines (Asch et al., 1987) has been reported. TSP is therefore thought to be implicated Abbreviations used: TSP, thrombospondin; BFU-E, burst-forming unit-erythroid; CFU-E, colony-forming unit-erythroid; MEL, murine erythroleukaemic (cell line); HEL, human erythroleukaemic cell line; GP, glycoprotein; BSA, bovine serum albumin; PBS, phosphate-buffered saline (composition and pH given in the text); PHA-LCM, phytohaemagglutinin/leucocyte-conditioned medium; Epo, erythropoietin;  in numerous cell-cell or cell-matrix interactions, promoting platelet aggregation (Leung, 1984) , plateletmonocyte/macrophage interaction , cell-substratum attachment and spreading (Tuszynski et al., 1987) , as well as adherence of Plasmodium falciparum (a malarial parasite)-infected erythrocytes to endothelial cells (Roberts et al., 1985a,b) . A role for TSP in cytoadhesion of human haematopoietic progenitor cells to the medullar microenvironment has recently been suggested by Long et al. (1987) , who demonstrated specific attachment of haematopoietic progenitor cells to immobilized purified TSP. So far, no cell-lineage-specific TSP receptor has been identified. In contrast, cell-surface sulphated glycolipids (Roberts et al., 1985a,b) and heparan sulphate proteoglycans (McKeown-Longo et al., 1984; Murphy-Ullrich & Mosher, 1987) have been reported to function as TSPbinding sites.
Recently, a monoclonal antibody (OKM5), reactive with platelets, endothelial cells and monocytes and identifying an 88 kDa cell-surface glycoprotein on C32 melanoma cells (Barnwell et al., 1985) has been shown to immunoprecipitate the 88 kDa glycoprotein (GP) IV from human platelets (Asch et al., 1987) . The antibody has further been used by Asch et al. (1987) to demonstrate that platelet GP IV functions as a cell-surface TSP receptor.
In the present study we used a monoclonal antibody (FA6-152) reacting with cells of the erythroid and megakaryocytic lineage to demonstrate the existence of a previously unidentified 78 kDa erythroid cell-surface glycoprotein whose expression is developmentally regulated during erythroid differentiation and which is immunologically related to the 88 kDa platelet TSP receptor.
MATERIALS AND METHODS Cell isolation and cell culture
Platelets. Blood (6 vol.) from healthy adult volunteers was taken into acid/citrate/dextrose (130 mM-citric acid/ 126 mM-trisodium citrate/ 10 mm dextrose) (1 vol.) and centrifuged at 120 g for 15 min at 20°C. Plateletrich-plasma was recovered and platelets isolated by repeated centrifugations in a modified Tyrode's buffer pH 6.5 [103 mM-NaCl/36 mM-citric acid/5 mM-KCI/ 2 mM-CaCl2/1 mM-MgCl2/5 mM-glucose/bovine serum albumin (BSA) (3.5 mg/ml; fraction V, Sigma, St. Louis, MO, U.S.A.)], containing 25 ug of apyrase (Sigma, grade I)/ml and 100 nM-prostaglandin El (Sigma) as previously described (Legrand et al., 1985) . The pellet was resuspended to a final platelet count of 2.5 x 108 platelets/ml in Tyrode's buffer, pH 7.4, containing 5 mMHepes and BSA (3.5 mg/ml).
Human fetal erythrocytes. Fetal blood samples were obtained by fetoscopy performed for antenatal diagnosis. Blood was collected into heparin and centrifuged for 10 min at 1800 g. The erythrocyte pellet was recovered and washed three times in phosphate-buffered saline (PBS; 137 mM-NaCl/2.7 mM-KCl/4.3 mMNa2HPO4,7H20/1.4 mM-KH2PO4, pH 7.3). The pellet was finally resuspended at 10' cells per ml in PBS.
Human fetal erythroid precursor cells. Fetal erythroid precursor cells were isolated from human fetal liver recovered 1 h after delivery from therapeutic abortion. The liver was placed into a Petri dish containing 5 ml of PBS and the liver cells isolated by gentle teasing of the tissue. The cell suspension was then transferred to a conical plastic tube and residual tissue aggregates eliminated after centrifugation of the cell suspension for 1 min at 50 g. HEL cells. HEL cells (Martin & Papayannopoulou, 1982) were cultured in RPMI medium (Boehringer, Mannheim, Germany) with 10 % (v/v) heat-inactivated fetal-calf serum (Boehringer) in a fully humidified atmosphere with 5 % CO2. Passages were performed every 3 days, and the cells were studied in the exponential phase of growth. Clonogeneic assays and indirect immunofluorescence Clonogeneic assays for blood BFU-E were performed by the plasma clot technique as described by McLeod et al. (1974) . The stimulating factors were phytohaemagglutinin/leucocyte-conditioned medium (PHA-LCM) plus 1 unit of porcine erythropoietin (Epo; CNTS, Paris, France)/ml. Fluorescence labelling with FA6-152 was performed directly in the culture dishes at day 6 or 7 of culture for immature erythroblasts and at day 12 of culture for mature cells as previously described (Vinci et al., 1984) . Cell labelling Surface labelling. Galactose and N-acetylgalactosamine residues on the cell surface were labelled by the neuraminidase/galactose oxidase/NaB3H4 method (Gahmberg & Hakomori, 1973) and sialic acid residues by the periodate/NaB3H4 method (Gahmberg & Andersson, 1977) ; cell-surface-protein iodination was performed using the lactoperoxidase-catalysed 1251-iodination procedure (Phillips & Agin, 1977 (Kieffer et al., 1986) . Briefly, cells in the exponential phase of growth were washed once in RPMI 1640 medium and resuspended at 2.5 x 106 cells/ml in methionine-free medium supplemented with 10 % (v/v) heat-inactivated dialysed fetal-calf serum. After 10 min at 37°C, [35S]methionine (50 ,tCi/ml) was added and the cells cultured for 3 h at 37 'C. Chymotrypsin digestion of surface-labelled platelets Washed platelets were resuspended at 109 platelets/ml in digestion buffer, pH 7.4 (10 mM-Tris/HCl/150 mMNaCl/ 1 mM-EDTA) and incubated for 2 min at 37 'C. Tosyl -lysylchloromethane (Tos -Lys -CH2Cl) -treated chymotrypsin from bovine pancreas (Sigma) was dissolved at 200 /iM in the same buffer and added to 1 ml aliquots of the platelet suspension to give a final concentration of 10 #M. After 10 min at 37 'C, phenylmethanesulphonyl fluoride (PMSF; Sigma; 100 mM; freshly prepared in ethanol) was added to a final concentration of 2 mm. Platelets were then pelleted by 1989 centrifugation for 15 min at 1200 g. The supernatant and platelet pellet were separately recovered.
Monoclonal antibodies and protein iodination
The monoclonal mouse antibody FA6-152 (IgGl) was purified from mouse ascites by affinity chromatography on protein A-Sepharose CL-4B (Pharmacia, Uppsala, Sweden) according to the manufacturer's instructions. The monoclonal rat IgG2a antibody SG1 1 , which does not bind to protein A, was purified from rat ascites by (NH4)2SO4 precipitation and DEAETrisacryl chromatography as described by Bazin et al. (1974) . Purified IgGs were radiolabelled with Na25I by the chloramine-T method to a specific radioactivity of 500 c.p.m./ng as previously described by Hunter & Greenwood (1962) . Radiolabelled IgGs were separated from residual free iodide by passage through a Sephadex G-25 column, saturated with BSA and equilibrated with PBS. More than 98 % of the radioactivity was precipitated by 200% (w/v) trichloroacetic acid. Protein concentration was determined spectrophotometrically by using an absorption coefficient (A'%0) of 1.48. BSA was added to a final concentration of 2 mg/ml, and the samples were stored at -80°C before use.
The monoclonal anti-(glycophorin A) antibody (LICR-LON-R1O) was kindly provided by Dr non-activated platelet samples (1.25 x 108/ml) were incubated for 30 min at room temperature with increasing concentrations of 125I-FA6-152 as detailed in the legend to Fig. 3 (below) . At the end of the incubation, duplicate 0.1 ml aliquots of each sample were layered on 0.5 ml of 20 % (w/w) sucrose and centrifuged for 5 min at 12000 g in an Eppendorf centrifuge. The supernatants were aspirated, and the radioactivity associated with the pellets was measured in a y-radiation counter (Beckman Instruments, Fullerton, CA, U.S.A.). Non-specific binding was determined by measuring residual radioactivity in the presence of a 20-fold excess of unlabelled antibody.
Effect of FA6-152 on TSP binding to the surface of thrombin-activated platelets. TSP expression on the surface of thrombin-stimulated platelets was measured by using 1251-5G1 1 as previously described (Legrand et al., 1988) . Unstirred washed platelet samples (2.5 x 108/ml) binding.
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Immunoprecipitation experiments and SDS/polyacrylamide-gel electrophoresis (PAGE) Immunoprecipitation experiments were performed as previously described by us (Kieffer et al., 1986) . Briefly, radiolabelled cells were lysed by resuspending the cell pellet in lysis buffer (10 mM-Tris/150 mM-NaCl/11/o Triton X-100/2 mM-PMSF, pH 7.4). Triton X-100-insoluble material was removed by centrifuging the samples at 100000 g for 30 min at 4 'C. Samples (200 #tg of protein in 200 #1) were incubated at 4 IC with 10 jug of FA6-152 IgG. After an incubation of 3 h, 25 1l of protein A-Sepharose CL-4B was added and the incubation continued for 1 h at 4 'C. Protein A-Sepharose beads were washed six times with lysis buffer, and the final pellet was resuspended in 50,tl of 10 mM-Tris/HCl, pH 7.4, containing 2 % (w/v) SDS and, when required, 5 0 2-mercaptoethanol. Bound proteins were eluted by heating the suspension at 100 'C for 5 min. The immune complexes were analysed by SDS/PAGE on 7-120%-(w/v)-polyacrylamide gradient slab gels as described by Laemmli (1970) . After electrophoresis, the gels were fixed, processed for fluorography with Amplify (Amersham International), dried and exposed for autoradiography at -80 'C to Kodak XAR-5 films (KodakPathe, Paris, France).
RESULTS

Immunochemical identification of the FA6-152 antigen on human platelets
The monoclonal antibody FA6-152, which was generated by immunizing mice with fetal erythrocytes, has previously been shown to react with both human erythroid cells and platelets (Edelman et al., 1986) . In the present study we have characterized the antigen identified by FA6-152. Immunoprecipitation experiments were performed using extracts of 3H-or 125I-surface-labelled platelets. The precipitates were analysed by SDS/PAGE, followed by fluorography. As Fig. 1 shows, FA6-152 precipitated a radiolabelled polypeptide from periodate/ NaB3H4-labelled platelets migrating with an apparent Mr of 88 kDa. An 88 kDa polypeptide was also precipitated when 125I-labelled platelets were tested (result not shown). When the neuraminidase/galactose oxidase/ NaB3H4 labelling procedure was used, which incorporates 3H into penultimate galactose residues, an 85 kDa polypeptide was observed. It is noteworthy that, in contrast with GP Ib, the major sialoglycoprotein of the platelet membrane, whose electrophoretic mobility decreases after neuraminidase treatment, the electrophoretic mobility of the FA6-152 antigen increased after cleavage of sialic acid. Reducing or non-reducing conditions did not affect the apparent molecular mass of the precipitated band. Since the erythroid-cell FA6-152 antigen has previously been shown to be resistant to proteolytic cleavage (Edelman et al., 1986) , we used this property to characterize the platelet antigen further. Immunoprecipitation experiments were performed on the pellet and supernatant of untreated and chymotrypsin-treated 3H-labelled platelets (Fig. 2) . Chymotrypsin treatment of whole 3H-surface-labelled platelets releases two major labelled glycopolypeptides, namely glycocalicin, the hydrophilic cleavage product of platelet GP Ib, and a large proteolytic fragment released from GP V (Berndt & Phillips, 1981 The samples were subjected to 7-12 % gradient acrylamide slab gels in the presence of 5 % 2-mercaptoethanol. Lanes A and B, total profile of 3H-surface labelled platelets ('3H') before (A) and after (B) chymotrypsin treatment; lanes C and D, supernatant ('S') of 3H-surface-labelled platelets before (C) and after (D) chymotrypsin treatment; lanes E and F, immunoprecipitate ('P') obtained with FA6-152 from Triton X-100-solubilized labelled platelets before (E) and after (F) chymotrypsin treatment; lanes G and H, immunoprecipitation ('IP') performed with FA6-152 on supernatants ('S') of platelets before (G) and after (H) chymotrypsin treatment. Standard molecular-mass markers are those indicated in the legend to Fig. I BFU-E colonies BFU-E-derived colonies were grown in plasma clot and stained at day 6 of culture with FA6-152, followed by fluorescein isothiocyanate-goat anti-mouse F(ab')2.
reacted with erythroid colonies as early as day 6 of culture. Fig. 4 (Berndt & Phillips, 1981; Tsuji & Osawa, 1986) . However, in contrast with GP IV, whose major characteristic is to be highly resistant to proteinase cleavage, GP V is a substrate for thrombin and is easily released from the cell surface by chymotrypsin treatment (Wicki & Clemetson, 1985) . The fact that the FA6-152 antigen was resistant to chymotrypsin treatment provides evidence that it does correspond to platelet GP IV, and excludes GP V as the possible antigen.
There The cell-surface density of GP IV is thus similar to that measured for another platelet membrane sialoglycoprotein, namely platelet GP Ib (Ruan et al., 1981; Coller et al., 1983) . It is noteworthy that the number of FA6-152 binding sites is also close to values reported for 1251-TSP binding to platelets (Wolff et al., 1986) , or the surface expression of endogenous TSP upon thrombin stimulation (Aiken et al., 1986; Legrand et al., 1988; Boukerche & McGregor, 1988) . To investigate further the role of GP IV in platelet surface TSP binding, we studied the effect of FA6-152 on endogenous TSP binding to human platelets. Preincubation of platelets with FA6-152 IgG (1 /cg/ml) (i.e. its Kd value) resulted in a 50 % inhibition of both the surface expression of TSP and platelet aggregation induced by low doses of a-thrombin. Since with higher doses of thrombin (0.1 unit), the FA6-152 induced inhibitory effect was overcome, our results suggest that GP IV is not the unique platelet TSP receptor. Indeed, Aiken et al. (1987a) have shown that more than one class of TSP binding sites exist at the platelet surface. Furthermore, a recent study by Tuszynski et al. (1988) has emphasized that GP IV is a receptor for TSP on unstimulated platelets and that other receptors are made available by thrombin stimulation. Since fibrinogen has been shown to bind TSP (Leung & Nachman, 1982) , thrombin-induced surfacebound fibrinogen molecules have to be considered as possible TSP-binding sites.
Immunofluorescence labelling studies performed with FA6-152 on bone-marrow cells and on cultures in vitro of BFU-E and CFU-E revealed that the FA6-152 antigen is a very early marker of erythroid differentiation and that its expression declines during maturation (Edelman et al., 1986) . Using immunochemical techniques we have now been able to characterize the FA6-152 antigen on human fetal erythroblasts as well as fetal reticulocytes. Our results demonstrate the existence of a previously unidentified 78 kDa surface glycoprotein in the erythroblast-cell membrane and its absence from mature adult erythrocytes. Under identical SDS/PAGE conditions, we observed a slight difference between the electrophoretic mobility (as expressed by Mr) of erythroid GP IV (78 kDa) and that of platelet GP IV (88 kDa). This result suggests that cell-lineage-specific differences in the carbohydrate moiety of the oligasaccharide chains might exist. In support of this hypothesis is the decrease in the apparent molecular mass of platelet GP IV from 88 to 85 kDa after neuraminidase treatment. Interestingly, when immunoprecipitations were performed on [35S]methionine-labelled HEL cells, which express both erythroid and megakaryocytic cell-surface markers, FA6-152 precipitated radiolabelled polypeptides of Mr 85000 and 88 000, two molecular masses observed for the platelet phenotype of GP IV.
The functional role of GP IV on erythroid cells is so far unknown. However, the developmentally regulated expression of GP IV, which parallels that observed for the fibronectin receptor (Patel & Lodish, 1986) , suggests that the decrease in the surface expression of both the fibronectin receptor and the TSP receptor could constitute one of the mechanisms involved in the release of differentiated erythrocytes from the interstitial matrix of the bone marrow into the blood stream. GP IV might also play an important role in the interaction of erythroid precursor cells with stromal cells. Since macrophages express GP IV as well as TSP, one might speculate that erythroid GP IV could be involved in the formation of the erythroblastic island composed of one or two macrophages surrounded by maturing erythroblasts (Bessis & Breton-Gorius, 1962) . In support of this hypothesis are the recent results obtained by Morris et al. (1988) , who have reported that murine fetal liver macrophages bind developing erythroblasts by a bivalent-cationdependent haemagglutinin. Taken together, the present data establish the existence of a previously unidentified 78 kDa erythroblast cellsurface glycoprotein whose expression is developmentally regulated during erythroid differentiation and which is immunologically related to the platelet thrombospondin receptor. Our results thus support the idea that not only the fibronectin receptor, but also the TSP receptor, could play a functional role in erythroid-cell attachment to bone-marrow stromal cells. Further studies will be necessary to demonstrate the functional role of erythroid GP IV in TSP binding and cell adhesion to the microenvironment of the bone marrow.
